article thumbnail

Overcoming Healthcare’s Mountain of Mistrust – Part 2: Payers

Perficient: Drug Development

To recap: Part 1 of the series focused on providers This part, Part 2, focuses on payers (insurance companies) Part 3 (by Marlana Voerster ) will focus on medical-device organizations First off: the bad news in trust for payers Gallup’s polling data among U.S. Ask them how they feel about both your company and their providers.

Nurses 52
article thumbnail

8 Frequently Asked Questions About Genetic Testing in Clinical Trials

Conversations in Drug Development Trends

This enables us to recruit patients ​quickly​​ ​and pinpoint optimal study locations to help our sponsors uncover new and potentially lifesaving treatments for people suffering from rare diseases. However, genetic tests can be expensive and may not be covered by insurance.